Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction
Wang L, Rodriguez-Ulloa A, Berlanga-Acosta J, García-Ojalvo A, Abreu-Cruz A, Gonzalez-López LJ, Besada-López V, Ramos-Gómez Y, Guillén-Nieto G, Jiang B
Summary
In a permanent coronary ligation model of myocardial infarction in rats, GHRP-6 administration (0.4 mg/kg) for 7 days post-infarct significantly attenuated myocardial tissue death, reduced interstitial fibrosis, and improved left ventricular systolic function. Mitochondrial proteomic analysis revealed upregulation of fatty acid beta-oxidation, anti-apoptotic pathways, and antioxidant defenses.
Clinical Significance
Growth hormone secretagogues like GHRP-6 continue to show promise as cardioprotective agents beyond their well-known GH-releasing effects. The mitochondrial metabolic reprogramming mechanism identified here provides a molecular rationale for further development of GHRP-class peptides in post-MI cardiac recovery, potentially complementing existing heart failure therapies.
Verwandte Forschung
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing signif…
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight redu…